NSB.AX up 43% pre-market 14 Jan 2026: NeuroScientific Biopharma volume spike
NSB.AX stock opened the pre-market session sharply higher after a large volume surge, trading at A$0.165 on 14 Jan 2026. The move shows a +43.48% change from the prior close and intraday range between A$0.145 and A$0.175. Volume is elevated at 5,803,773 shares versus an average of 213,564, signaling outsized retail or short-covering interest ahead of clinical or corporate catalysts.
NSB.AX stock pre-market snapshot
NeuroScientific Biopharmaceuticals Limited (NSB.AX) trades on the ASX in Australia and shows a market cap of A$38,246,206. Key session metrics include price A$0.165, previous close A$0.115, and open A$0.16. Shares outstanding are 332,575,706.
Valuation signals are mixed: EPS is -0.01 and reported PE is -11.50. Price-to-book sits near 0.99, which equals the company book value per share of A$0.1151.
Catalysts, news flow and trading drivers
There is no formal ASX market release tied to today’s jump, but biotech peers and clinical-readout chatter often move microcap names. NSB.AX shows increased social engagement on its official channels and modest institutional interest.
Investors should watch the next earnings and corporate calendar item: the earnings announcement date is listed as 24 Feb 2026. Short covering dynamics are possible given low liquidity historically.
NSB.AX stock financials and valuation
On fundamentals, NeuroScientific sits in the Healthcare sector and Biotechnology industry. Trailing metrics show a high current ratio near 49.56, cash per share A$0.0497, and negative free cash flow per share -A$0.0064. Revenue per share is A$0.00, reflecting a pre-revenue biotech profile.
Growth data to 30 Jun 2024 show mixed trends: five-year revenue per share growth was positive, while R&D expense declined year-on-year. Analysts should treat ratios as early-stage biotech indicators, not stable corporate earnings signals.
Technical view and high-volume signals
The technical set shows short-term momentum. RSI is 53.91, CCI at 179.77 flags overbought conditions, and MFI is 82.65, another overbought signal on heavy money flows. Bollinger middle band is A$0.11 and ATR is A$0.01, pointing to elevated volatility.
High volume of 5,803,773 versus average 213,564 suggests price moves are volume-driven. For traders, watch intraday support near A$0.145 and resistance near the year high A$0.26.
Meyka AI grade and model outlook for NSB.AX stock
Meyka AI rates NSB.AX with a score out of 100: 66.21 | Grade B | HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
Meyka AI’s forecast model projects a 12‑month median around A$0.22. That projection compares to the current price A$0.165 and implies a potential upside of about 33.12%. Forecasts are model-based projections and not guarantees. For source context, see comparative market data source and view the company page on Meyka NSB.AX on Meyka.
Final Thoughts
NSB.AX stock is the day’s high volume mover on the ASX, trading A$0.165 pre-market on 14 Jan 2026 with volume near 5.80 million shares. The jump reflects active trading interest and potential short-covering in a small-cap biotech with negative EPS and tight liquidity. Technical indicators show overbought signals, so intraday reversals are possible.
Meyka AI’s forecast model projects a 12‑month price near A$0.22, which implies roughly 33.12% upside from the current A$0.165. That outlook balances model gains against clear risks: negative earnings, limited revenue, and biotech regulatory uncertainty. Traders focusing on high-volume setups should size positions for volatility and track upcoming company updates and the 24 Feb 2026 earnings window. Use the Meyka AI platform for real-time alerts and deeper metric screens before taking positions.
FAQs
What moved NSB.AX stock higher pre-market today?
NSB.AX stock rose on heavy volume of 5,803,773 shares versus average 213,564. The move looks volume-driven, likely from retail interest or short covering rather than a formal ASX announcement.
What are the key valuation metrics for NSB.AX stock?
Key metrics: price A$0.165, market cap A$38,246,206, EPS -0.01, PE -11.50, and price-to-book about 0.99. The company is pre-revenue with cash per share A$0.0497.
How does Meyka AI rate NSB.AX stock?
Meyka AI rates NSB.AX with a score out of 100: 66.21, Grade B, suggestion HOLD. The grade uses benchmarks, sector comparison, growth and analyst data. Grades are not guarantees.
What is the short-term trading outlook for NSB.AX stock?
Short-term outlook is volatile. Technicals show RSI 53.91 and overbought CCI and MFI. Watch support A$0.145 and resistance near the year high A$0.26. Trade with stop-loss rules.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
